Navigation Links
Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
Date:12/5/2012

BSi attains pre-specified lead candidate selection criteria, Cerecor plans to sign an exclusive, world-wide license agreement and assume development of the lead DAAO inhibitor candidate(s). JHU will receive an initial license fee and additional payments based upon achievement of specified development and commercialization milestones as well as royalties on net sales.

In 2013, Cerecor intends to complete the technology transfer activities and further examine the development and clinical profile of the lead candidate(s). This strategic evaluation will further inform potential implications for an early development clinical program.

About Cerecor:  Cerecor Inc is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and co-founded in April 2011 by Drs. Solomon Snyder, Barbara Slusher, Blake Paterson and Mr. Isaac Blech. Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.

CONTACT: Karen Krumeich, +1-410-522-8707


'/>"/>
SOURCE Cerecor Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dr. Magnus Persson Joins Cerecors Board of Directors
2. Cerecor Announces Initiation of CLIN01-002-A
3. Savient Announces the Election of Robert G. Savage to its Board of Directors
4. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
5. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
6. Tria Beauty, Inc. Announces Partnership with Jenny McCarthy
7. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
8. UBM Canon Announces its New Medical Technology Seminar Series
9. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
10. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
11. Ultra Clean Announces Participation in the Midtown CAP Summit Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 Amgen ... today announced results from several exploratory analyses of the ... low bone mineral density (BMD). Romosozumab is an investigational ... the protein sclerostin, thereby increasing bone formation and decreasing ... Society for Bone and Mineral Research (ASBMR) 2014 Annual ...
(Date:9/15/2014)... 2014 myMatrixx has extended its contract with ... an expanded role that includes direct involvement in the ... nationally recognized physiatrist and pain management specialist, published author, ... workers, compensation, is Board Certified in physical medicine and ... Pain Medicine and subspecialty boarded by the American Board ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
(Date:9/15/2014)... 15, 2014 The Best Hospitals ... Report consists of seven hospitals using OnBase as their ... and Cleveland Clinic were ranked at the top of ... The rankings cover nearly 5,000 medical centers across the ... hospitals that scored highest in at least six of ...
(Date:9/15/2014)... Randy Dotinga HealthDay Reporter ... Patients prescribed cholesterol-lowering drugs are more likely to fill ... are cheaper generic brands, new research suggests. At ... brands include Crestor, Zocor and Lipitor. Generic statins are ... risk of heart problems due to clogged arteries. ...
(Date:9/15/2014)... Worth, FL (PRWEB) September 15, 2014 ... policy away from putting low-level offenders in jail and ... Treatment Group sees this shift as a positive change. ... of prescription drug and heroin abuse. According to an ... both parties are calling for a shift away from ...
(Date:9/15/2014)... By Dennis Thompson ... (HealthDay News) -- The severe respiratory virus believed to ... Western states has now spread to the Northeast, health ... Health confirmed on Friday more than a dozen cases ... especially for children with asthma. And on Saturday, ...
(Date:9/15/2014)... 15, 2014 Array Health ... technology, today announced that Independence Blue Cross ... southeastern Pennsylvania, has selected the Array Spectrum™ Private ... exchange marketplace for employers with more than 100 ... Spectrum™, Independence will offer employer groups a comprehensive ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 3Health News:White House Shifts Policy on Drugs 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3
... East Hills, NY (Sept. 19, 2007) -- Each year ... critical part of their donation literally go down the ... collected annually, a majority (about two-thirds) of the four ... banks are replacing this valuable resource with much more ...
... Former Speaker of the,House and founder of the ... of conservative Republican lawmakers on Capitol Hill,today that while ... over the State Children,s Health Insurance Program (SCHIP) is ... insistent that Congress,not lose sight of the hundreds of ...
... Inc.,(OTC: ABOS) today announced Walter C. Ogier has resigned as ... of Directors. The Arbios Board,of Directors has appointed Shawn P. ... and CEO. The Company plans to,initiate a search for a ... Board of Directors has elected Amy,Factor as Vice Chairman. Ms. ...
... The majority of parents feel they play a ... according to researchers at the University of Michigan C.S. ... in the October issue of the Journal of Pediatrics, ... decisions made about their hospitalized childs medical care. Researchers ...
... million Americans who are living with cancer or have ... keeping their spirits intact: communication. In recognition of this, ... report by November 1, co-authored by a University of ... to good cancer care and deserves more research. , ...
... factor found at higher levels in these tumors, scientists say ... called nerve growth factor (NGF) may prove an effective target ... NGF is an essential component in the growth and differentiation ... in the Oct. 7 issue of the World Journal ...
Cached Medicine News:Health News:Critical blood shortages eased by new technology 2Health News:Critical blood shortages eased by new technology 3Health News:Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a 'Clean' SCHIP Six-Month Extension 2Health News:Arbios Announces Management Changes 2Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Communication in cancer world is key to survival 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: